Ofer Haviv - 18 Mar 2026 Form 3 Insider Report for Evogene Ltd. (EVGN)

Role
President and CEO, Director
Signature
/s/ Nitsan Deutsch, attorney-in-fact
Issuer symbol
EVGN
Transactions as of
18 Mar 2026
Net transactions value
$0
Form type
3
Filing time
18 Mar 2026, 08:06:13 UTC
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Haviv Ofer President and CEO, Director 13 URI ZVI GRINBERG, TEL AVIV, ISRAEL /s/ Nitsan Deutsch, attorney-in-fact 18 Mar 2026 0001981700

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding EVGN Stock Option (right to buy ordinary shares) 18 Mar 2026 Ordinary shares 22,500 $51.96 Direct
holding EVGN Stock Option (right to buy ordinary shares) 18 Mar 2026 Ordinary shares 50,000 $10.50 Direct
holding EVGN Stock Option (right to buy ordinary shares) 18 Mar 2026 Ordinary shares 52,800 $1.66 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The options reported in this row vest and become exercisable over a period of four years from the December 23, 2024 grant date. 25% of the options vested and became exercisable upon the one-year anniversary of the grant date and the remainder of the options vest and become exercisable equally on a quarterly basis (6.25% per quarter) over the following twelve quarters such that all options will be fully vested and exercisable on the four-year anniversary of the grant date.

Remarks:

Exhibit 24.1 - Power of Attorney.